Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical Center | Zendy

Joshua D. Hartzell | Zendy; Robert Neff | Zendy; Julie A. Ake | Zendy; Robin Howard | Zendy; Stephen W. Olson | Zendy; Kristopher Paolino | Zendy; Mark Vishnepolsky | Zendy; Amy Weintrob | Zendy; Glenn Wortmann | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical Center

Author(s) -

Joshua D. Hartzell,

Robert Neff,

Julie A. Ake,

Robin Howard,

Stephen W. Olson,

Kristopher Paolino,

Mark Vishnepolsky,

Amy Weintrob,

Glenn Wortmann

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/599225

Subject(s) - medicine , nephrotoxicity , rifle , acute kidney injury , tertiary care , colistin , incidence (geometry) , intensive care medicine , toxicity , antibiotics , physics , archaeology , optics , biology , microbiology and biotechnology , history

The incidence of acute renal failure, defined by the risk, injury, or failure criteria of the RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease), in 66 patients who received colistimethate sodium was 45%, and 21% of patients stopped therapy because of nephrotoxicity. The RIFLE criteria should be used in the future to allow for comparison of nephrotoxicity among studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research